BridgeBio Infigratinib Data Shows Respiratory and Metabolic Benefits

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported that oral infigratinib delivered favorable trends in respiratory and metabolic health metrics during the 52-week PROPEL 3 study. The data suggests the therapy offers benefits that extend beyond the primary endpoint of height increase, addressing comorbidities such as sleep apnea and otitis media that commonly affect children with achondroplasia.

According to the clinical update reported by GN markets/health, the treatment group showed a significantly lower increase in the apnea-hypopnea index compared to the placebo group. While the placebo cohort experienced a 49.2% rise in the total index, the infigratinib group saw a 10.4% increase from baseline. These results indicate a potential reduction in the severity of breathing disturbances associated with the condition.

Respiratory and Infection Metrics Improve

The study highlighted specific advantages for younger patients, with children under eight years old showing no change in apnea-hypopnea index when treated with infigratinib. In contrast, the placebo group for this age bracket recorded a 63.2% increase in the index. This divergence suggests the drug may stabilize respiratory function in the most vulnerable demographic, where airway obstruction is a critical clinical concern.

Infigratinib was also associated with a reduced frequency of ear infections. The estimated annualized rate of otitis media was 38% lower in the treatment group compared to the placebo group. Among children younger than eight, the reduction in infection rates reached 47%, indicating a substantial impact on the infectious comorbidities that often accompany narrowed ear canals in achondroplasia.

Body Composition Shifts Toward Lean Mass

Metabolic outcomes favored the infigratinib group, which exhibited a smaller increase in Body Mass Index over the 52-week period. The treatment group’s BMI rose by 0.50 kg/m², whereas the placebo group’s BMI increased by 0.93 kg/m². This difference suggests that the therapy helps manage weight gain, a common challenge for patients with this skeletal dysplasia.

Further analysis of body composition revealed that infigratinib promoted a more favorable distribution of mass. Lean body mass increased by 1.77 kg in the treatment group compared to 1.58 kg in the placebo group. Conversely, the increase in total body fat mass was lower at 0.95 kg versus 1.12 kg for placebo. Visceral fat volume also showed a marked difference, rising by only 1.55 mL in the treatment group compared to a 18.42 mL increase in the placebo group.

Regulatory Pathway Targets Mid-2027 Launch

BridgeBio positions oral infigratinib as the first and only approved oral therapy for pediatric achondroplasia. The company has already submitted a New Drug Application to the U.S. Food and Drug Administration and anticipates a commercial launch in the United States by mid-2027. This timeline aligns with the company’s strategy to establish a dedicated treatment option for this rare genetic disorder.

Internationally, the company plans to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026. This dual-track regulatory approach underscores the commercial potential of the drug in both major markets. The clinical data presented provides the evidentiary basis for these submissions, highlighting a broader therapeutic profile that includes respiratory and metabolic benefits.